Occlusive thrombosis in the femoral artery of the rabbit: A pharmacological model for evaluating antiplatelet and anticoagulant agents

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 1, 1996, Pages 57-64

  Sugidachi, A ^a   Asai, F ^a   Tani, Y ^b   Hosokawa, T ^b   Koike, H ^a  

^a DAIICHI SANKYO CO   (Japan)

^b SK10 4TJ

Author keywords

Antithrombotic agent; Arterial thrombosis; Blood coagulation; Platelet activation; Vessel injury

Indexed keywords

6 (2 CHLOROPHENYL) 8 DIPROPYLCARBAMOYL 8,9 DIHYDRO 1 METHYL 4H,7H CYCLOPENTA[4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; ACETYLSALICYLIC ACID; APROSULATE; HEPARIN; NICARDIPINE; PHENYLALANYLPROLYLARGININE CHLOROMETHYLKETONE; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BLOOD VESSEL INJURY; CONTROLLED STUDY; FEMORAL ARTERY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT;

EID: 0029980291     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199601000-00007     Document Type: Article

References (40)

1. Hladovec J. Experimental arterial thrombosis in rats with continuous registration. Thromb Diath Haemorrh 1973; 29: 407-410.
2. Schumacher WA, Heran CH, Steinbacher JR, et al. Thrombin inhibition compared with other antithrombotic drugs in rats. Thromb Res 1992; 68: 157-166.
3. Kaiser B, Markwardt F. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. Thromb Haemostas 1986; 55: 194-196.
4. Rote WE, Davis JH, Mousa SA, Reilly TM, Lucchesi BR. Antithrombotic effects of DMP 728, a platelet GpIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. J Cardiovasc Pharmacol 1994; 23: 681-689.
5. Bevilacqua C, Finesso M, Prosdocimi M. Acute carotid artery occlusive thrombosis and its pharmacological prevention in the rabbit. Thromb Res 1991; 62: 263-273.
6. Kurz KD, Main BW, Sandusky GE. Rat model of arterial thrombosis induced by ferric chloride. Thromb Res 1990; 60: 269-280.
7. 2. Thromb Haemostas 1992; 68: 460-463.
8. Philp RB, Francey I, Warren BA. Comparison of antithrombotic activity of heparin, ASA, sulfinpyrazone and VK 744 in a rat model of arterial thrombosis. Haemostasis 1978; 7: 282-293.
9. Bernat A, Mares AM, Defreyn G, Maffrand JP, Herbert JM. Effects of various antiplatelet agents on acute arterial thrombosis in the rats. Thromb Haemostas 1993; 70: 812-816.
10. Kornowski R, Glikson M, Ohad D, Varda-Bloom N, Battler A. Electrical injury in the femoral artery of rabbits as a model for arterial thrombosis: a pilot study. Angiology 1994; 45: 295-300.
11. Fujii S, Abendschein DR, Sobel BE. Augmentation of plasminogen activator inhibitor type I activity in plasma by thrombosis and by thrombolysis. J Am Coll Cardiol 1991; 18: 1547-1554.
12. Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis parameters in animals. Arzneim-Forsch/Drug Res 1994; 44: 793-797.
13. 3H]-platelet activating factor (PAF) to the platelet. Biochem Pharmacol 1985; 34: 1941-1945.
14. David JL, Monfort F, Herion F, Raskinet R. Compared effects of three dose-levels of ticlopidine on platelet function in normal subjects. Thromb Res 1979; 14: 35-49.
15. Burke SE, Lefer AM, Micolaou KC, Smith GM, Smith, JB. Responsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogues. Br J Pharmacol 1983; 78: 287-292.
16. Lee TC, Malone B, Blank ML, Snyder F. 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) stimulates calcium influx in rabbit platelets. Biochem Biophys Res Commun 1981; 102: 1262-1268.
17. Abela GS, Picon PD, Friedl SE, et al. Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 1995; 91: 776-784.
18. Kornowski R, Meltzer RS, Chernine A, Vered Z, Battler A. Does external ultrasound accelerate thrombolysis? Results from a rabbit model. Circulation 1994; 89: 339-344.
19. Brill-Edwards P, Ryn-McKenna JV, Cai L, Ofosu FA. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits: implications for antithrombotic therapy. Thromb Haemostas 1992; 68: 424-427.
20. Raake W, Klauser RJ, Elling H, Meinetsberger E. Anticoagulant and antithrombotic properties of synthetic sulfated bis lactobionic acid amides. Thromb Res 1989; 56: 719-730.
21. Ali ATMM, Al-Humayyd MS. Enhancement of antithrombotic effect of aspirin by metoclopramide in rats. Thromb Res 1991; 61: 361-367.
22. Weiss HJ, Hoffmann T, Turitto VT, Nemerson Y. Further studies on the presence of functional tissue factor activity on the subendothelium of normal human and rabbit arteries. Thromb Res 1994; 73: 313-326.
23. Pawashe AB, Golino P, Ambrosio G, et al. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries. Circ Res 1994; 74: 56-63.
24. Samama CM, Bonnin P, Bonneau M, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemostas 1992; 68: 500-505.
25. Schumacher WA, Heran CL, Steinbacher TE, Youssef S, Ogletree ML. Superior activity of a thromboxane receptor antagonist as compared with aspirin in rat models of arterial and venous thrombosis. J Cardiovasc Pharmacol 1993; 22: 526-533.
26. Hess H, Mietaschk A, Deichsel G. Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; i: 415-419.
27. Steering committee of the physician health study research group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989; 321: 129-135.
28. McTavish D, Faulds D, Goa KL. Ticlopidine. An update review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-259.
29. Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. New Engl J Med 1984; 311: 1206-1211.
30. Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262.
31. Cattaneo M, Akkawat B, Lecchi A, et al. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemostas 1991; 66: 694-699.
32. Heuer HO. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs. J Lipid Mediat 1991; 4: 39-44.
33. Sorkin EM, Clissold SP. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1987; 33: 296-345.
34. Tapparelli C, Metternich R, Ehrhardt C, Cook NS. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. TiPS 1993; 14: 366-376.
35. Kettner C, Shaw E. D-Phe-Pro-Arg-CH2-Cl - a selective affinity label for thrombin. Thromb Res 1979; 14: 969-973.
36. Rosenberg RD. Biochemistry of heparin antithrombin interaction, and the physiologic role of this natural anticoagulant mechanism. Am J Med 1989; 87: 2S-9S.
37. Klauser RJ, Raake W, Meinetsberger E, Zeiller P. Antithrombotic and anticoagulant properties of synthetic polyanions: sulfated bis-aldonic acid amides. J Pharmacol Exp Ther 1991; 259: 8-14.
38. Sugidachi A, Asai F, Koike H. In vivo pharmacology of aprosulate, a new synthetic polyanion with anticoagulant activity. Thromb Res 1993; 69: 71-80.
39. Klauser RJ. Interaction of the sulfated lactobionic acid amide LW 10082 with thrombin and its endogenous inhibitors. Thromb Res 1991; 62: 557-565.
40. Sugidachi A, Asai F, Koike H. Anticoagulant and antiprotease activities of aprosulate, a new synthetic polyanion, in human plasma and purified systems. Blood Coag Fibrinol 1994; 5: 773-779.